| Revenue H1 FY27 | ₹133.23 Cr75% YoY Increase |
|---|---|
| Net Profit H1 | ₹5.15 Cr55% YoY Increase |
| Order Book | ₹468 CrStandalone Basis |
| Market Cap | ₹445.96 CrHealthcare Sector |
Key highlights
- Consolidated revenue rose 75% YoY to ₹133.23 crore in H1 FY27
- Net profit increased 55% YoY to ₹5.15 crore with an EPS of ₹4.18
- Order book stood at ₹468 crore as of September 2026, more than double the March level
- Management raised annual revenue growth guidance to 70-80% from earlier 30-40%
- Receivables reached ₹129 crore due to milestone-linked payments on major projects
Pharma and Renewables Drive Robust Revenue Performance
Fabtech Cleanrooms Limited demonstrated strong top-line momentum in the first half of FY27, with consolidated revenue reaching ₹133.23 crore. The growth was primarily driven by the standalone business, which more than doubled its revenue to ₹107 crore compared to the same period last year. Management highlighted that the order book has diversified significantly, with pharmaceutical and life sciences orders growing from ₹42 crore to ₹217 crore.
The renewable energy segment also contributed ₹195 crore to the standalone order book, indicating a successful pivot toward high-growth infrastructure sectors beyond traditional healthcare.
Order Book Composition and Pipeline Visibility
- Standalone order book reached ₹468 crore by September 30, 2026
- Pharmaceutical and Life Sciences segment accounts for ₹217 crore of the backlog
- Renewable Energy segment contributes ₹195 crore to the current order book
- Data centers and semiconductors represent ₹56 crore in orders
- Hot pipeline of approximately ₹600 crore identified out of ₹1,250 crore in active offers
- Secured a landmark ₹92 crore contract for Meril Life Sciences
Management Confidence in Aggressive FY27 Targets
The growth this growth is not an accident and it is not a one-off. It is a result of a strategy we have run without deviation since our first earning call. We are talking the walk, we are walking the talk.
Operational Headwinds and Margin Outlook
Despite the sharp revenue jump, EBITDA margins remained largely flat at 7.67% compared to 7.61% in the previous year. Management attributed this to high volatility in raw material costs, particularly aluminum and steel, which saw prices double within short windows. Additionally, receivables climbed to ₹129 crore, which the company explained as a strategic choice to accept milestone-linked payments on reference projects to displace multinational competitors.
Management expects working capital pressure to ease by March 2027 as project milestones are met and high-margin billing kicks in during the second half of the fiscal year.
Strategic Expansion and Regulatory Tailwinds
- Operationalized a new Hyderabad plant adding 50,000 square meters of capacity
- Currently executing a 75,000 square meter cleanroom project, the largest in its history
- Benefiting from revised Schedule M rules requiring pharmaceutical upgrades in India
- Leveraging Indian-cell mandates in the solar sector to drive cleanroom demand
- Aiming to become the largest integrated cleanroom player in India by 2030
What to watch next
- Consolidation of receivables and working capital relief expected by March 2027
- Execution of the ₹600 crore hot pipeline identified for H2 FY27
- Commissioning of advanced automated lines at the Umargam and Hyderabad facilities
- Impact of raw material cost settling on H2 FY27 EBITDA margins, targeted at 10-12%
“Our order book stands at 468 crores as of 30th September, more than double where it was in March. It is also better balanced. Pharma and Life Sciences account for about 217 crores.”
“We have finalized the biggest ticket in the industry for pharma thus far, 92 crores for Meril Life Sciences for medical high-end medical diagnostics.”
| Share price | ₹362 |
|---|---|
| Market capitalisation | ₹445.96 Cr |
| Revenue (annual) | ₹219.32 Cr |
| Net profit (annual) | ₹15.82 Cr |
| P/E (TTM) | 28.2×Sector 53.84× |
| Promoter holding | 68.49% |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Fabtech Cleanrooms Limited announcing H1 FY27 financial performance and updated guidance. Market figures from a third-party data provider.
